Qishenyiqi Dripping Pill for Coronary Microvascular Disease
NCT ID: NCT06699420
Last Updated: 2024-11-21
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
PHASE4
162 participants
INTERVENTIONAL
2023-11-08
2026-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Tongxinluo Capsule for Coronary Microvascular Disease
NCT04220372
Effect of Ticagrelor on Adenosine-Induced Coronary Flow Reserve in Patients With Microvascular Angina
NCT02284048
Evaluate the Efficacy and Safety of MUSK Pill on Coronary Microvascular Dysfunction
NCT04984954
Ticagrelor in Elderly Patients Undergoing Percutaneous Coronary Intervention
NCT04999293
A sTudy of Low Dose vs Standard Dose of tIcaGrelor on Platelet Function After intErvention for Acute Coronary syndRome in Diabetes Mellitus Patients
NCT04307511
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Qishenyiqi Dripping Pill
Qishenyiqi dripping pills 1 bag, three times a day
Qishenyiqi dripping pills, 1 bag once, three times a day, 12 months
Placebo
Placebo 1 bag, three times a day
Placebo, 1 bag once, three times a day, 12 months
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Qishenyiqi dripping pills 1 bag, three times a day
Qishenyiqi dripping pills, 1 bag once, three times a day, 12 months
Placebo 1 bag, three times a day
Placebo, 1 bag once, three times a day, 12 months
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Coronary normal or stenosis \< 20%;
* Ischemic depression in ST segment during resting or exercise;
* Blood flow reserve (CFR) of the anterior descending coronary artery \< 2.0;
* Subjects or their guardians agreed to participate in this study.
Exclusion Criteria
* A history of heart failure;
* Severe arrhythmia;
* Refractory hypertension or hypertension accompanied by left ventricular wall thickness \> 12 mm;
* Familial hypercholesterolemia;
* Takayasu arteritis, Kawasaki disease or coronary artery malformation;
* Pregnant or nursing, or having the intention to give birth within one year;
* Hepatic or renal dysfunction;
* Allergic to contrast agents or traditional Chinese medicines;
* Patients who participated in clinical research of other drugs within 3 months before being selected.
40 Years
75 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Qilu Hospital of Shandong University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Pan-Pan Hao
Prof.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Qianfoshan Hospital, Shandong University
Jinan, Shandong, China
Qilu Hospital of Shandong University
Jinan, Shandong, China
Jinan Central Hospital Affiliated to Shandong First Medical University
Jinan, Shandong, China
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
Qishenyiqi for CMVD
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.